Abstract
The objectives of this study are to determine whether patients with overactive bladder (OAB) and nocturia achieved relief of their nighttime voiding symptoms when treated with solifenacin and whether having nocturnal polyuria (NP) affected that response. The patients pooled from four phase III clinical trials were evaluated for reductions in nocturia episodes after treatment with solifenacin (5 or 10 mg) or placebo. A second analysis was performed in patients with and without NP. The patients treated with solifenacin experienced statistically significant reductions in nocturia episodes; median reductions were −35.5% for 5 mg of solifenacin and −36.4% for 10 mg of solifenacin compared with −25.0% for placebo, and significantly more patients treated with solifenacin vs placebo achieved a mean nocturic frequency of ≤1 episode/night. Solifenacin significantly reduced nocturia episodes only in patients without NP (mean change was −0.61 episodes/night for both doses compared with −0.43 episodes for placebo). Solifenacin significantly improved nocturia symptoms only in OAB patients without NP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183
Lundgren R (2004) Nocturia: a new perspective on an old symptom. Scand J Urol Nephrol 38:112–116
Svatek R, Roche V, Thornberg J, Zimmern P (2005) Normative values for the American Urological Association Symptom Index (AUA-7) and short form Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting for non-urological care. Neurourol Urodyn 24:606–610
Asplund R, Marnetoft SU, Selander J, Akerstrom B (2005) Nocturia in relation to somatic health, mental health and pain in adult men and women. BJU Int 95:816–819
Kobelt G, Borgstrom F, Mattiasson A (2003) Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 91:190–195
Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E (2003) The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92:948–954
Stewart RB, Moore MT, May FE, Marks RG, Hale WE (1992) Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 40:1217–1220
Asplund R (1999) Mortality in the elderly in relation to nocturnal micturition. BJU Int 84:297–301
Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178
Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924
Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310
Gittelman M, Chu F, Klimberg I, Fincher R, Smith N, Tempel D, Ridge S (2003) Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 (solifenacin succinate; Vesicare®) versus placebo in male and female subjects with overactive bladder. Poster presented at the American Urological Association Annual Meeting; April 26–May 1, 2003; Chicago, IL (on behalf of the YM905 Study Group)
van Elteren PH (1960) On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Stat 37:351–361
Weiss JP, Blaivas JG (2000) Nocturia. J Urol 163:5–12
Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL (2005) Nocturnal polyuria in women with overactive bladder symptoms and nocturia. Am J Obstet Gynecol 192:1682–1686
Weiss JP, Blaivas JG, Stember DS, Brooks MM (1998) Nocturia in adults: etiology and classification. Neurourol Urodyn 17:467–472
Johnson TM II, Burgio KL, Redden DT, Wright KC, Goode PS (2005) Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 53:846–850
Kreder KJ Jr, Brubaker L, Mainprize T (2003) Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 92:418–421
Chapple C, Steers W, Norton P et al (2005) A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95:993–1001
Hill S, Khullar V, Wyndaele JJ, Lheritier K (2005) Dose response with darifenacin, a novel once-daily M(3) selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17(3):239–247
Acknowledgement
The authors would like to thank Linda Gorman, Ph.D. and Ellen Lewis, Ph.D. of Envision Pharma for their assistance with the writing and preparation of this manuscript. Funding for the analysis of this data was provided by Yamanouchi Pharma America (now Astellas) and GlaxoSmithKline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brubaker, L., FitzGerald, M.P. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J 18, 737–741 (2007). https://doi.org/10.1007/s00192-006-0239-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-006-0239-y